SG Americas Securities
DYN icon

SG Americas Securities’s Dyne Therapeutics DYN Stock Holding History

SG Americas Securities’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.04M Sell
112,626
-152,758
-58% -$2.63M ﹤0.01% 1385
2025
Q4 		$5.19M Buy
+265,384
New +$5.03M 0.01% 1076
2025
Q3 		– Sell
-12,768
Closed -$122K – 3424
2025
Q2 		$122K Sell
12,768
-417,283
-97% -$4.59M ﹤0.01% 2550
2025
Q1 		$4.5M Buy
430,051
+411,015
+2,159% +$5.88M 0.01% 502
2024
Q4 		$448K Buy
19,036
+692
+4% +$20.5K ﹤0.01% 1431
2024
Q3 		$659K Buy
18,344
+12,207
+199% +$486K ﹤0.01% 1447
2024
Q2 		$217K Buy
+6,137
New +$178K ﹤0.01% 2133
2024
Q1 		– Sell
-12,938
Closed -$172K – 3083
2023
Q4 		$172K Buy
+12,938
New +$126K ﹤0.01% 2301
2023
Q2 		– Sell
-11,183
Closed -$129K – 2505
2023
Q1 		$129K Buy
11,183
+1,380
+14% +$17.9K ﹤0.01% 2741
2022
Q4 		$114K Sell
9,803
-418
-4% -$4.84K ﹤0.01% 2631
2022
Q3 		$130K Sell
10,221
-530
-5% -$6.08K ﹤0.01% 2646
2022
Q2 		$74K Buy
+10,751
New +$74.1K ﹤0.01% 3204
2021
Q4 		– Sell
-71,317
Closed -$1.16M – 3489
2021
Q3 		$1.16M Buy
+71,317
New +$1.26M 0.01% 1775

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

SG Americas Securities's DYN Position: Q1 2026 in Review

SG Americas Securities reduced its Dyne Therapeutics (DYN) stake by 58% in Q1 2026, selling an estimated $2.63M and leaving 112,626 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

SG Americas Securities first reported a position in DYN in Q3 2021 and has held it in 13 quarters since. The position peaked at $5.19M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • SG Americas Securities held 112,626 shares of Dyne Therapeutics worth $2.04M as of Q1 2026.
  • SG Americas Securities sold 152,758 Dyne Therapeutics shares in Q1 2026, an estimated $2.63M.
  • Dyne Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1385 holding.
  • SG Americas Securities first reported a position in Dyne Therapeutics in Q3 2021 and has held it in 13 quarters since.
  • SG Americas Securities's Dyne Therapeutics position peaked at $5.19M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.